The conventional understanding of Alzheimer's disease may need revision as emerging evidence reveals that the brain's own immune defenders could be fueling the very pathology they're meant to combat. This discovery fundamentally challenges the assumption that amyloid plaques form passively through protein misfolding alone. New laboratory findings demonstrate that human macrophages and microglia—immune cells tasked with brain protection—actively produce Aβ42 fibrils, the most toxic form of amyloid protein associated with neurodegeneration. These immune-generated fibrils exhibit potent seeding capabilities, meaning they can trigger the formation of additional plaques throughout brain tissue. The research reveals a previously unknown mechanism where the immune system inadvertently becomes complicit in disease progression rather than serving purely protective functions. This represents a significant departure from traditional models that viewed immune activation primarily as a response to existing pathology. The implications extend beyond basic science to therapeutic strategy, suggesting that treatments targeting immune cell behavior could be as crucial as those addressing amyloid accumulation directly. However, this single-study finding requires extensive replication before clinical applications can be considered. The work was conducted using laboratory cell cultures, and whether this mechanism operates similarly in living human brains remains to be established. If confirmed through additional research, this discovery could explain why some individuals develop Alzheimer's despite lower overall amyloid burdens, and why immune-modulating interventions have shown mixed results in clinical trials. The finding represents potentially paradigm-shifting insight into neurodegeneration mechanisms.